HIV/AIDS Vaccine
Recombinant canarypox vaccine is safe and immunogenic in HIV-1-exposed newborns
Published in Vaccine Weekly, January 18th, 2006
According to a study from the United States, "Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks."
"The vaccines were safe. Lymphoproliferative responses were detected at {{>=}}2 time points in 44%-56% of vaccinees and none of the placebo recipients," the authors reported.
"A cytotoxic T...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-01-18)
More Articles from Vaccine Weekly
- Diabetes Vaccine
Protein Sciences to produce diabetes vaccine for phase III trials - Influenza A Virus
Improved influenza A virus generation may improve vaccine production - Nicotine Vaccine
Nicotine conjugate vaccine elicits dose-related immunogenicity in tobacco smokers - West Nile Virus
West Nile vaccine begins Phase I clinical study - Anthrax
U.S. FDA rules anthrax vaccine safe - Anthrax Toxin
Anthrax toxins directly inhibit T-lymphocyte activation - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
